http://www.youtube.com/watch?v=yXMddEIdusg[EXTRACT]
Dr. Samuel Aguiar Jr. - Hospital do Câncer - AC CamargoMédico do Departamento de Cirurgia Pélvicahttp://199.238.143.96/index.php?option=com_content&task=view&id=29&Itemid=33
The Bonnie J. Addario Lung Cancer Foundation invites you to join The Living Room, a lively and interactive online support group for those who are directly and indirectly affected by lung cancer. The April Living Room will feature a patient-focused program, titled “Sharing My Personal Journey.” There’s no guest speaker this month, just stories and experiences from patients and family who can offer hope to others.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56176-bjalcf-the-living-room-online-support-group-sharing-my-personal-journey
Susan G. Komen for the Cure®, the world’s leading breast cancer organization, today launched a major new outreach to dramatically improve cancer screening, education and outreach in the Latina community, where breast cancer is the leading cause of cancer death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50756-susan-g-komen-for-the-cure-latina-community-improve-breast-cancer-outreach
Since it launched Choose You in May 2010, the American Cancer Society has motivated more than 75,000 people, most of them women, to put their health at the top of their to-do lists. Choose You raises awareness about the simple actions people can take that can significantly reduce their risk of cancer, and reminds people of the sobering statistic that one in three women will get cancer in her lifetime. The Society urges women to join the movement at ChooseYou.com to help change the odds.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cancer/50026/
The American Cancer Society today announces the development of a new documentary film in collaboration with Academy Award-winning Actress Hilary Swank to inspire women nationwide to make their own health a priority and take everyday steps to help prevent cancer. Swank is executive producer of the film alongside Molly Mickler Smith of 2S Films and Go Go Luckey Entertainment, and the film is directed by Tina Gazzerro of Go Go Luckey Entertainment. The film helps mark the first anniversary of Choose You, a nationwide movement created by the American Cancer Society to raise awareness that 1 in 3 women will get cancer in her lifetime and the actions women can take today to help change that statistic. More than half of cancer deaths could be prevented if people maintained a healthy weight through diet and regular exercise, avoided tobacco products and got recommended cancer screening tests.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cancer/50276/
I feel fabulous, not flabulous, how about you? Check me and The Buttons out as we Get Waisted. In line with our single release, Mama Mio will give a donation for every Get Waisted sold through http://www.mamamio.com/uk/belle-and-t... or through Debenhams to cancer support charity Look Good...Feel Better.
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced the opening of a state-of-the-art research center in Billerica, MA, establishing it as a “hub” within the Merck KGaA research organization. Representing a $65 million investment, the Billerica research facility supports the company’s commitment to developing and discovering innovative treatments in oncology, neurodegenerative diseases and infertility. Nearly 100 new jobs will be added in Massachusetts as a result of the building expansion.
To view Multimedia News Release, go to
http://multivu.prnewswire.com/mnr/emdserono/48166/
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Nearly five black women die needlessly per day from breast cancer in the United States – a total of 1,722 deaths annually – according to a study released today at the Avon Foundation Breast Cancer Forum and simultaneously published in Cancer Epidemiology. The 2012 Racial Disparity in Breast Cancer Mortality Study found that 21 of the 25* largest U.S. cities have a black: white disparity in breast cancer mortality, 13 of which are statistically significant.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52895-avon-foundation-breast-cancer-forum-racial-disparity-mortality-study
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
